Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index - 14/12/17
, Lone Skov, MD, PhD, DMSc a, Carsten R. Hamann, MD a, Gunnar H. Gislason, MD, PhD b, c, d, Alexander Egeberg, MD, PhD aAbstract |
Background |
There is a growing interest in comorbidities of adults with atopic dermatitis (AD).
Objectives |
To examine the burden of comorbidities in adult patients with AD using the Charlson comorbidity index (CCI) in nationwide registries.
Methods |
All Danish patients ≥18 years on January 1, 2012 with AD diagnosed by a hospital dermatologist were included. Patients were age-and sex-matched in a 1:4 ratio with general population controls. Severity was determined by systemic AD treatment and analyzed by conditional logistic regression.
Results |
In total, 10,738 adult patients with AD and 42,952 controls were analyzed. CCI score was significantly increased in smokers with AD compared with controls (0.41 vs 0.13, P < .001). Nonsmokers with AD had a similar CCI score as controls (0.09 vs 0.08, P = .12). In analyses restricted to patients with severe AD, a stronger difference in CCI score was observed for smokers (0.48 vs 0.14, P < .001) than for nonsmokers (0.10 vs 0.08, P = .01).
Limitations |
Observational studies do not establish cause and effect.
Conclusion |
On the basis of nationwide data, the risk for major comorbidities was significantly increased in adult patients with AD compared with controls. The risk difference was predominantly found in patients with severe disease and among smokers.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, comorbidity, epidemiology, risk, smoking
Abbreviations used : AD, CCI, CV, CVD, ICD
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation and has attended advisory board meetings for Roche and Sanofi-Genzyme. Dr Skov has received consultancy and speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Hamann has no relevant conflicts of interest to declare. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Dr Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria for consulting and speaking for Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. |
|
| Reprints not available from the authors. |
Vol 76 - N° 6
P. 1088 - juin 2017 Retour au numéro
Article précédent
- The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study
- Carmen Liy-Wong, Javed Mohammed, Amanda Carleton, Elena Pope, Patricia Parkin, Irene Lara-Corrales
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska, Nan Zhang, Bruce Strober
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?